Yifei Wang

6PUBLICATIONS
23CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 24, 2026
MYC-bound enhancer RNAs in cis regulate gene transcription and tumorigenesis.

|Apr 09, 2026
CRISPR activation screens identify oncogenic lncRNAs that are susceptible to CDK4/6 inhibitor treatment.

Yifei Wang, Yueshan Zhao, Jiaxin Hu

|Aug 12, 2025
The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition.

Dhamotharan Pattarayan, Yue Wang, Zehua Wang

|May 05, 2025
Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance.

Haozhe Huang, Yiqing Mu, Yixian Huang

|Apr 12, 2024
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer.

Yue Wang, Dhamotharan Pattarayan, Haozhe Huang

|Dec 08, 2022
Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response.

Yifei Wang, Yueshan Zhao, Weiwei Guo

Pageof 1

Frequent Collaborators

6 joint publications

Da Yang

5 joint publications

Dhamotharan Pattarayan

5 joint publications

Song Li

4 joint publications

Xiaofei Wang